Cart
sales@molnova.com
Balanophonin
CAS No. 118916-57-7
Balanophonin( —— )
Catalog No. M30856 CAS No. 118916-57-7
Balanophonin shows potent α-glucosidase inhibitory activity, it has antioxidant, and anti-cancer activities. (±)-Balanophonin shows significant antibacterial activity against cariogenic oral streptococci, Streptococcus mutans and S. sobrinus.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 511 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameBalanophonin
-
NoteResearch use only, not for human use.
-
Brief DescriptionBalanophonin shows potent α-glucosidase inhibitory activity, it has antioxidant, and anti-cancer activities. (±)-Balanophonin shows significant antibacterial activity against cariogenic oral streptococci, Streptococcus mutans and S. sobrinus.
-
DescriptionBalanophonin shows potent α-glucosidase inhibitory activity, it has antioxidant, and anti-cancer activities. (±)-Balanophonin shows significant antibacterial activity against cariogenic oral streptococci, Streptococcus mutans and S. sobrinus.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number118916-57-7
-
Formula Weight356.4
-
Molecular FormulaC20H20O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SantacruzaMate A
Santacruzamate A (CAY10683) is a potent and selective HDAC inhibitor.
-
Siplizumab
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
-
NRX-252262
NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation(EC50:3.8 nM)
